In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Intarcia gets $215mm in first close of Series EE financing round; adds $206mm in second close

Executive Summary

Metabolic disease-focused Intarcia Therapeutics Inc. received $215mm in late-stage equity financing from institutional investors, family offices, and China's Lucion Venture Capital Group. The company expects to receive additional funding in Q4. Intarcia will use the proceeds to help with the regulatory approval and launch (expected late next year) of its ITCA650 (exenatide) for Type II diabetes. Morgan Stanley was the placement agent.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register